Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
NCT04174755Recruiting
- Sponsor
- University College Dublin
- Start
- Jun 2022
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in obesity comparing Semaglutide 0.25/0.5/1 mg plus standard of care with Standard of care alone (2 arms). Primary endpoint: Changes in total body weight at 28 weeks. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04174755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174755.